ICVX

Icosavax, Inc. Common Stock

ICVX

Market cap $769M

Delisted

ICVX was delisted on the 16th of February, 2024.

Back to rankings

About: Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.

Employees: 60

Healthcare Drug Manufacturers - General

Financial journalist opinion

ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Icosavax, Inc. (NASDAQ: ICVX) to AstraZeneca for $15.00 per share in cash plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, is fair to Icosavax shareholders. The tender offer in connection with the proposed transaction is currently set to expire on or around January 26, 2024. Halper Sade.

ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders

ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Icosavax, Inc. (NasdaqGS: ICVX) to AstraZeneca. Under the terms of the proposed transaction, shareholders of Icosavax will receive $15.00 in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, for.

ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Icosavax, Inc. (NasdaqGS: ICVX) to AstraZeneca. Under the terms of the proposed transaction, shareholders of Icosavax will receive $15.00 in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, for.

ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

Zacks Investment Research

Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know

Does Icosavax, Inc. (ICVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research

Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade

Icosavax, Inc. (ICVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders?

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Icosavax, Inc. (NASDAQ: ICVX) breached their fiduciary duties in connection with the proposed sale of the Company to AstraZeneca. You can click or copy and paste the following link to join this investigation: https://www.johnsonfistel.com/investigations/Icosavax-co On November 30, 2023, Icosavax announced that it had entered a deal to merge with AstraZeneca.

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders?

Why AstraZeneca Is Buying Icosavax For $1.1 Billion

Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vaccine technology.

Shareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZeneca

MILWAUKEE , Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Icosavax (Nasdaq: ICVX) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca. Click here to learn how to join the https://www.ademilaw.com/case/icosavax-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZeneca

AstraZeneca will pay up to $1.1B to acquire Icosavax, a Univ. of Washington biotech spinout

Seattle-based Icosavax, a spin-out from the University of Washington's Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to $1.

See News Rankings

Charts implemented using Lightweight Charts™